Lipid-efficacy RCT · J Am Coll Cardiol 2023
SPORT trial
Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.
The bottom line
In people with elevated ASCVD risk but no prior ASCVD, low-dose rosuvastatin (5 mg) lowered LDL-C far more than placebo or any of six common dietary supplements, which showed no significant LDL-C benefit over placebo.
Primary lipid endpoint metUS status: US-approved
At a glance
- Medicine
- Rosuvastatin 5 mg daily
- Compared with
- Placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice
- People
- 190
- Who took part
- Adults with no history of atherosclerotic cardiovascular disease (ASCVD), an LDL-C of 70 to 189 mg/dL, and an increased 10-year risk of ASCVD
- Design
- single-center, prospective, randomized, single-blind clinical trial
- Follow-up
- 28 days
- Main question
- Percent change in LDL-C from baseline for rosuvastatin 5 mg daily compared with placebo and each supplement after 28 days
Main result
The percent LDL-C reduction with rosuvastatin was greater than all supplements and placebo (P < 0.001). The difference in LDL-C reduction with rosuvastatin compared with placebo was -35.2% (95% CI: -41.3% to -29.1%; P < 0.001).
Effect on LDL cholesterol
Difference in LDL-C reduction with rosuvastatin compared with placebo was -35.2% (95% CI: -41.3% to -29.1%; P < 0.001); none of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo.
Safety
Adverse event rates were similar across study groups.
In the trial's own words
“The difference in LDL-C reduction with rosuvastatin compared with placebo was -35.2% (95% CI: -41.3% to -29.1%; P < 0.001). None of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo.”
Quoted from the abstract of J Am Coll Cardiol 2023, checked word for word against PubMed. PubMed 36351465 · Full paper (DOI)
How this medicine works, where it stands and what it costs: Statins
Common questions
What did the SPORT trial find?
In people with elevated ASCVD risk but no prior ASCVD, low-dose rosuvastatin (5 mg) lowered LDL-C far more than placebo or any of six common dietary supplements, which showed no significant LDL-C benefit over placebo.
Who was in SPORT?
190 people. Adults with no history of atherosclerotic cardiovascular disease (ASCVD), an LDL-C of 70 to 189 mg/dL, and an increased 10-year risk of ASCVD.
What was SPORT's main result?
The percent LDL-C reduction with rosuvastatin was greater than all supplements and placebo (P < 0.001). The difference in LDL-C reduction with rosuvastatin compared with placebo was -35.2% (95% CI: -41.3% to -29.1%; P < 0.001).
How much did LDL cholesterol change in SPORT?
Difference in LDL-C reduction with rosuvastatin compared with placebo was -35.2% (95% CI: -41.3% to -29.1%; P < 0.001); none of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo.
Related trials
- LODESTAR (2023)In patients with coronary artery disease, rosuvastatin and atorvastatin provide similar long-term cardiovascular protection, but rosuvastatin carries a higher risk of new-onset diabetes requiring medication and cataract surgery.
- REPRIEVE (2023)In people with HIV at low-to-moderate cardiovascular risk, daily pitavastatin significantly reduced major adverse cardiovascular events compared with placebo, though with modestly more muscle symptoms and diabetes.
- SAMSON (2021)In patients who had previously stopped statins due to side effects, symptom scores were equally elevated on statin and placebo compared with no treatment, indicating most statin-associated symptoms are a nocebo effect rather than a pharmacological effect of the drug.
- StatinWISE (2021)In patients with prior statin-associated muscle symptoms, atorvastatin 20 mg did not cause more muscle symptoms than placebo when tested in a blinded n-of-1 design, and most participants intended to resume statin therapy.
Get your LDL treated to a goal
Preval Health's protocols follow trials like this one. Licensed clinicians set your goal, prescribe and recheck until you reach it.
Get startedEducation only, not medical advice. Results describe the people in this trial and can differ for you. Talk with your clinician before starting or stopping any medicine. Back to all 106 trials.